Ambu's revenues and earnings disappoint despite top-line growth
Growth in the second quarter is a little weaker than the consensus estimate, while the Danish medtech company’s profit has seen a sharp year-over-year drop.
by marketwire, translated by daniel pedersen
Despite a growing top line, Ambu’s second-quarter growth in financial year 2022/2023 looks a little weaker than what analysts had anticipated, for example sliding back from the profit of the same quarter a year before.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analyst sees Ambu endoscope sales as driving growth
For subscribers
Ambu finds new COO at biotech firm
For subscribers
Mexico plant weighs down Ambu's climate account
For subscribers
